GFP/Luc Reporter Cell Line - Hep3B

The Hep3B cell line is a well-established human hepatocellular carcinoma (HCC) model, originally derived in 1979 from the hepatic tumor of an 8-year-old patient. Growing as an adherent epithelial monolayer, it is uniquely characterized by the presence of an integrated Hepatitis B virus (HBV) genome, which results in the continuous production of the hepatitis B surface antigen (HBsAg). Furthermore, the cells harbor a p53-null mutation and secrete major hepatic plasma proteins such as alpha-fetoprotein (AFP) and albumin. The GFP/Luc Reporter Cell Line - Hep3B represents a sophisticated dual-labeled derivative of this foundational liver cancer model. Through stable lentiviral transduction, these cells are engineered to constitutively co-express both green fluorescent protein (GFP) and the firefly luciferase enzyme. This dual genetic integration ensures that the cells simultaneously emit a robust bioluminescent signal upon exposure to the substrate D-luciferin and display bright green fluorescence under appropriate light excitation. Crucially, this modification transforms the standard line into a versatile, dual-modality tracking tool while strictly preserving its original malignant phenotype, HBV-positive status, and baseline cellular morphology.

Leveraging its accurate representation of HBV-associated hepatocellular carcinoma, this dual-reporter cell line is an invaluable resource for pre-clinical oncology and virology research. In vivo, the constitutive bioluminescence enables the establishment of highly translational orthotopic liver models and systemic xenografts. By utilizing non-invasive bioluminescence imaging (BLI), researchers can continuously monitor localized primary hepatic tumor growth and dynamically evaluate the efficacy of experimental therapeutics in living animals over time, eliminating the need for repeated endpoint sacrifices. Concurrently, the robust GFP expression facilitates precise ex vivo histological analysis, enabling the high-resolution spatial tracking of tumor margins, intrahepatic invasion, and distant metastasis. In vitro, the dual optical readouts streamline high-throughput cell viability and cytotoxicity screening. Scientists rely on the green fluorescence for live-cell microscopy and flow cytometry, while utilizing the quantifiable bioluminescent signal to rapidly assess the direct cytotoxic impact of novel chemotherapeutics, targeted kinase inhibitors, and emerging immunotherapies directed against virus-driven hepatic malignancies.